Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database

OBJECTIVE: To compare the risk of malignancy between patients with rheumatoid arthritis (RA) initiating their first biological disease-modifying antirheumatic drug (bDMARD) and those continuing conventional synthetic DMARDs (csDMARDs). METHODS: Nine-year historical Propensity Score (PS) matched coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Seror, Raphaele, Lafourcade, Alexandre, De Rycke, Yann, Pinto, Sandrine, Castaneda, Johann, Fautrel, Bruno, Mariette, Xavier, Tubach, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226991/
https://www.ncbi.nlm.nih.gov/pubmed/35738803
http://dx.doi.org/10.1136/rmdopen-2021-002139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226991/
https://www.ncbi.nlm.nih.gov/pubmed/35738803
http://dx.doi.org/10.1136/rmdopen-2021-002139

Ejemplares similares